- Home
- CELU vs SRTS Comparison
CELU vs SRTS Comparison
Compare CELU & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- SRTS
- Stock Information
- Founded
- CELU 2016
- SRTS 2010
- Country
- CELU United States
- SRTS United States
- Employees
- CELU N/A
- SRTS 54
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- CELU Health Care
- SRTS Health Care
- Exchange
- CELU Nasdaq
- SRTS Nasdaq
- Market Cap
- CELU 56.9M
- SRTS 67.5M
- IPO Year
- CELU N/A
- SRTS 2016
- Fundamental
- Price
- CELU $1.96
- SRTS $4.11
- Analyst Decision
- CELU Strong Buy
- SRTS Strong Buy
- Analyst Count
- CELU 1
- SRTS 3
- Target Price
- CELU $6.00
- SRTS $8.00
- AVG Volume (30 Days)
- CELU 69.1K
- SRTS 173.8K
- Earning Date
- CELU 11-14-2025
- SRTS 11-06-2025
- Dividend Yield
- CELU N/A
- SRTS N/A
- EPS Growth
- CELU N/A
- SRTS N/A
- EPS
- CELU N/A
- SRTS N/A
- Revenue
- CELU $40,578,000.00
- SRTS $35,609,000.00
- Revenue This Year
- CELU N/A
- SRTS N/A
- Revenue Next Year
- CELU $76.00
- SRTS $47.33
- P/E Ratio
- CELU N/A
- SRTS N/A
- Revenue Growth
- CELU N/A
- SRTS N/A
- 52 Week Low
- CELU $1.00
- SRTS $3.03
- 52 Week High
- CELU $4.35
- SRTS $9.31
- Technical
- Relative Strength Index (RSI)
- CELU 57.50
- SRTS 58.41
- Support Level
- CELU $1.62
- SRTS $3.81
- Resistance Level
- CELU $2.29
- SRTS $4.34
- Average True Range (ATR)
- CELU 0.15
- SRTS 0.30
- MACD
- CELU 0.06
- SRTS -0.01
- Stochastic Oscillator
- CELU 63.29
- SRTS 46.76
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.